Global Preeclampsia Drugs Market, By Type (Mild Preeclampsia, Severe Preeclampsia), Treatment (Medication to Lower B.P., Corticosteroids and Anticonvulsants Medication), Route of Administration (Oral, Parenteral, Others), End User (Hospitals, Specialty Clinics, Diagnostic Centers and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2030.
Preeclampsia Drugs Market Analysis and Size
The occurrence of preeclampsia, a precursor to eclampsia, varies greatly globally. WHO estimates the occurrence of preeclampsia to be seven times higher in developing countries (2.8% of live births) than in developed countries (0.4%). Several market players that are operating in the market announce novel products to augment the demand for the product. As per the Swiss Medical Weekly, risks for developing pre-eclampsia includes nulliparity, pre-existing hypertension, prior pre-eclampsia, renal disease.
Data Bridge Market Research analyses a growth rate in the preeclampsia drugs market in the forecast period 2023-2030. The expected CAGR of preeclampsia drugs market is tend to be around 10% in the mentioned forecast period. The market was valued at USD 1 billion in 2022, and it would grow upto USD 2.14 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Preeclampsia Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Mild Preeclampsia, Severe Preeclampsia), Treatment (Medication to Lower B.P., Corticosteroids and Anticonvulsants Medication), Route of Administration (Oral, Parenteral, Others), End User (Hospitals, Specialty Clinics, Diagnostic Centers and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Thermo Fisher Scientific Inc. (U.S.), Baxter (U.S.), Bayer AG (Germany), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthcare GmbH (Germany), PerkinElmer Inc (U.S.), Sera Prognostics (U.S.), DRG INSTRUMENTS GMBH (Germany), Metabolomic Diagnostics (Ireland), Diabetomics, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Preeclampsia is a pregnancy complication that is characterized by high blood pressure and signs of damage to another organ system, specifically the liver and kidneys. Preeclampsia generally begins after 20 weeks of pregnancy in women whose B.P. had been normal. It is typically characterized by a sudden onset of high blood pressure, extreme swelling of the hands and face, and dysfunctionality of a few organs that may not work normally, including protein in the urine.
Global Preeclampsia Drugs Market Dynamics
Drivers
- Increasing Incidence of Preeclampsia
According to the records of American Heart Association, Inc., the greatest morbidity and mortality, preeclampsia affects around 5% to 7% of all pregnant women; though, it is responsible for over 70, 000 maternal deaths and 500,000 fetal deaths worldwide each year. Thus, this increasing prevalence demands high use of drugs which benefits the market growth.
- Growing Prevalence of Lifestyle Diseases
As per the American Diabetes Association, cardiovascular disease, cancer, and diabetes account for around two-thirds of the total deaths in the U.S. and US$ 700 billion in direct and indirect economic costs every year. These diseases undermine health, cause enormous suffering and disability, shorten life expectancy, and cost high economic cost. The doctor may suggest a daily low-dose aspirin beginning after 12 weeks of pregnancy. Patients also might benefit from several calcium supplements to prevent preeclampsia. Thus, this factor enhances the market size.
Opportunities
- Availability of different diagnostic tests
There are several diagnostic tests that are available for diagnosing preeclampsia drugs are creating much opportunities for the market growth. The development of innovative preeclampsia diagnostic procedure is projected to improve the adoption of the diagnostic procedure. The rising incidence of the disorder in pregnant women across the globe is anticipated to enhance the diagnostics’ adoption. For instance, according to the NCBI’s research published in July 2021, preeclampsia incidence in France reached around 8.5% among pregnant women. These factors may drive the preeclampsia diagnostics market growth.
- Increasing Demand for Advanced Treatments
Several women having preeclampsia drugs are treated caesarean C-section to have a lower risk of complications. During labor and following delivery, people with preeclampsia are often given magnesium intravenously to prevent the development of eclampsia. This creates more opportunity for the market growth.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified healthcare professionals who cannot perform these treatments could reduce the growth of the global preeclampsia drugs market during the forecast period.
- High Cost
The huge expenditure required for the surgeries and treatment processes hamper the market growth. Numerous market players make huge investment in installing new and advanced treatment procedures to faster the recovery process and in return the cost is increased.
This preeclampsia drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the preeclampsia drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Preeclampsia Drugs Market
This market is positively impacted during the pandemic because of the increasing demand for preeclampsia diagnostics procedures from the healthcare sector. The growing cases of preeclampsia led to the rapid adoption of several treatment processes and diagnostic procedures. Additionally, in the post pandemic era, government guidelines such as amendments encouraging the adoption of such procedures are projected to increase the demand for the product. Furthermore, market players experienced a huge spike in revenues because of the procedure’s extensive adoption. These factors influenced the industry growth during the pandemic
Recent Development:
- In July 2021, LifeCell Diagnostics announced a comprehensive preeclampsia screening in India. The aim is to detect biomarker, sFLT-1 (soluble FMS-like tyrosine kinase-1), which will enable the prediction of the disease and helps in the accurate diagnosis even in the third trimester of pregnancy
Global Preeclampsia Drugs Market Scope
The preeclampsia drugs market is segmented on the basis of type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Mild Preeclampsia
- Severe Preeclampsia
Treatment
- Medication to Lower B.P
- Corticosteroids
- Anticonvulsants Medication
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Specialty Clinics
- Diagnostic Centers
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Preeclampsia Drugs Market Regional Analysis/Insights
The preeclampsia drugs market is analyzed and market size insights and trends are provided by type, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the preeclampsia drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
America dominates the market in the forecast period due to the growing recognition among patients and health care providers about the seriousness of the disease
Asia-Pacific is considered the most lucrative period due to increased healthcare spending and the adoption of technologically advanced medicines which will increase the preeclampsia drugs market growth in the region
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Preeclampsia Drugs Market Share Analysis
The preeclampsia drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to preeclampsia drugs market.
Key players operating in the preeclampsia drugs market include:
- Thermo Fisher Scientific Inc. (U.S.)
- Baxter (U.S.)
- Bayer AG (Germany)
- Merck & Co., Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Siemens Healthcare GmbH (Germany)
- PerkinElmer Inc (U.S.)
- Sera Prognostics (U.S.)
- DRG INSTRUMENTS GMBH (Germany)
- Metabolomic Diagnostics (Ireland)
- Diabetomics, Inc. (U.S.)
SKU-